Concepts in Immuno-oncology: Tackling B Cell Malignancies with CD19-directed Bispecific T Cell Engager Therapies

Overview

Journal Ann Hematol

Specialty Hematology

Date 2020 Aug 29

PMID 32856140

Citations 19

Authors

Andreas Viardot

Franco Locatelli

Julia Stieglmaier

Faraz Zaman

Elias Jabbour

Affiliations

Soon will be listed here.

Abstract

The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is approved for relapsed/refractory B cell precursor acute lymphoblastic leukemia and B cell precursor acute lymphoblastic leukemia with minimal residual disease. Blinatumomab is also being evaluated in combination with other agents (tyrosine kinase inhibitors, checkpoint inhibitors, and chemotherapy) in various treatment settings, including frontline protocols. An extended half-life BiTE molecule is also under investigation. Patients receiving blinatumomab may experience cytokine release syndrome and neurotoxicity; however, these events may be less frequent and severe than in patients receiving other CD19-targeted immunotherapies, such as chimeric antigen receptor T cell therapy. We review BiTE technology for treating malignancies that express CD19, analyzing the benefits and limitations of this bispecific T cell engager platform from clinical experience with blinatumomab.

Citing Articles

Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions.

Ding J, Yeong C Front Oncol. 2024; 14:1504139.

PMID: 39703856 PMC: 11655346. DOI: 10.3389/fonc.2024.1504139.

Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies.

Olejarz W, Sadowski K, Szulczyk D, Basak G Int J Mol Sci. 2024; 25(14).

PMID: 39062986 PMC: 11276786. DOI: 10.3390/ijms25147743.

Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.

Mikhailova E, Popov A, Roumiantseva J, Budanov O, Lagoyko S, Zharikova L J Immunother Cancer. 2024; 12(6).

PMID: 38844406 PMC: 11163637. DOI: 10.1136/jitc-2023-008213.

Cost and cost-effectiveness of immunotherapy in childhood ALL: A systematic review.

Scoleri-Longo Y, Pechlivanoglou P, Gupta S EJHaem. 2024; 5(1):166-177.

PMID: 38406535 PMC: 10887368. DOI: 10.1002/jha2.814.

Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics.

Poveda-Garavito N, Combita A Front Immunol. 2024; 14:1325255.

PMID: 38299154 PMC: 10827891. DOI: 10.3389/fimmu.2023.1325255.

References

Scheuermann R, Racila E . CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995; 18(5-6):385-97. DOI: 10.3109/10428199509059636. View

Lamb Y . Inotuzumab Ozogamicin: First Global Approval. Drugs. 2017; 77(14):1603-1610. DOI: 10.1007/s40265-017-0802-5. View

Gokbuget N . How I treat older patients with ALL. Blood. 2013; 122(8):1366-75. DOI: 10.1182/blood-2012-07-379016. View

Lee K, Chow V, Weissman A, Tulpule S, Aldoss I, Akhtari M . Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults. Ther Clin Risk Manag. 2016; 12:1301-10. PMC: 5003562. DOI: 10.2147/TCRM.S84261. View

Gokbuget N . Treatment of older patients with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):573-579. PMC: 6142461. DOI: 10.1182/asheducation-2016.1.573. View

Hunger S, Mullighan C . Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015; 373(16):1541-52. DOI: 10.1056/NEJMra1400972. View

Fielding A, Richards S, Chopra R, Lazarus H, Litzow M, Buck G . Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2006; 109(3):944-50. DOI: 10.1182/blood-2006-05-018192. View

Jabbour E, OBrien S, Konopleva M, Kantarjian H . New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015; 121(15):2517-28. PMC: 11726371. DOI: 10.1002/cncr.29383. View

Locatelli F, Schrappe M, Bernardo M, Rutella S . How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012; 120(14):2807-16. DOI: 10.1182/blood-2012-02-265884. View

10.

Epperla N, Hamadani M . Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. Hematol Oncol Stem Cell Ther. 2017; 10(4):277-284. DOI: 10.1016/j.hemonc.2017.05.004. View

11.

Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch D, Trneny M . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(27):4184-90. PMC: 3664033. DOI: 10.1200/JCO.2010.28.1618. View

12.

Chavez J, Bachmeier C, Kharfan-Dabaja M . CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019; 10:2040620719841581. PMC: 6466472. DOI: 10.1177/2040620719841581. View

13.

Yuraszeck T, Kasichayanula S, Benjamin J . Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment. Clin Pharmacol Ther. 2017; 101(5):634-645. PMC: 5763312. DOI: 10.1002/cpt.651. View

14.

Baeuerle P, Reinhardt C . Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009; 69(12):4941-4. DOI: 10.1158/0008-5472.CAN-09-0547. View

15.

Vinay D, Ryan E, Pawelec G, Talib W, Stagg J, Elkord E . Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-S198. DOI: 10.1016/j.semcancer.2015.03.004. View

16.

Nagorsen D, Kufer P, Baeuerle P, Bargou R . Blinatumomab: a historical perspective. Pharmacol Ther. 2012; 136(3):334-42. DOI: 10.1016/j.pharmthera.2012.07.013. View

17.

Viardot A, Goebeler M, Hess G, Neumann S, Pfreundschuh M, Adrian N . Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016; 127(11):1410-6. PMC: 4797019. DOI: 10.1182/blood-2015-06-651380. View

18.

Stein A, Franklin J, Chia V, Arrindell D, Kormany W, Wright J . Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Drug Saf. 2018; 42(5):587-601. PMC: 6475509. DOI: 10.1007/s40264-018-0760-1. View

19.

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

20.

Slaney C, Wang P, Darcy P, Kershaw M . CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment. Cancer Discov. 2018; 8(8):924-934. DOI: 10.1158/2159-8290.CD-18-0297. View